Aemetis’ (AMTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Aemetis (NASDAQ:AMTX) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $28.00 price objective on the specialty chemicals company’s stock.

A number of other equities research analysts also recently commented on AMTX. Truist Financial reaffirmed a “hold” rating and issued a $3.50 target price (down previously from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. StockNews.com upgraded Aemetis to a “sell” rating in a research report on Wednesday, July 31st. Ascendiant Capital Markets dropped their target price on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Finally, UBS Group cut their price target on Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Aemetis presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.95.

Aemetis Price Performance

Aemetis stock opened at $3.83 on Friday. Aemetis has a one year low of $2.10 and a one year high of $7.03. The business’s fifty day moving average is $2.80 and its 200 day moving average is $3.05. The stock has a market capitalization of $190.50 million, a PE ratio of -1.69 and a beta of 1.23.

Aemetis (NASDAQ:AMTX) last posted its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million for the quarter, compared to the consensus estimate of $77.79 million. During the same quarter in the prior year, the company posted ($0.59) EPS. As a group, sell-side analysts expect that Aemetis will post -2.1 EPS for the current fiscal year.

Institutional Trading of Aemetis

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of Aemetis by 7.7% in the third quarter. Geode Capital Management LLC now owns 924,293 shares of the specialty chemicals company’s stock worth $2,126,000 after buying an additional 66,031 shares during the period. Barclays PLC increased its holdings in Aemetis by 274.6% in the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock worth $109,000 after acquiring an additional 34,816 shares in the last quarter. Wellington Management Group LLP bought a new stake in Aemetis during the 3rd quarter worth approximately $177,000. State Street Corp lifted its holdings in Aemetis by 36.1% during the third quarter. State Street Corp now owns 699,089 shares of the specialty chemicals company’s stock valued at $1,608,000 after purchasing an additional 185,304 shares in the last quarter. Finally, FMR LLC lifted its holdings in Aemetis by 68.2% during the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after purchasing an additional 9,137 shares in the last quarter. Institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.